Synthesis of some new quinoxalines and 1,2,4-triazolo[4,3-a]-quinoxalines for evaluation of in vitro antitumor and antimicrobial activities

Archiv der Pharmazie

Volumn 339, Issue 10, 2006, Pages 564-571

  El Hawash, Soad A M ^a   Habib, Nargues S ^a   Kassem, Mervat A ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

1 Substituted 3 phenylquinoxalin 2(1H) ones; 1 Substituted 4 phenyl 1,2,4 triazolo 4,3 a quinoxalines; 2 Hydrazino 3 phenylquinoxaline; Anticancer; Antimicrobial activity

Indexed keywords

1 (ARYLCARBONYLMETHYL) 3 PHENYLQUINOXALINE 2(1H) ONES; 1 (N ARYLCARBAMOYLMETHYL) 3 PHENYLQUINOXALINE 2(1H) ONES; 1 ETHOXYCARBONYL 4 PHENYL 1,2,4 TRIAZOLO[4,3 A] QUINOXALINE; 1 METHYL 4 PHENYL 1,2,4 TRIAZOLO[4,3 A]QUINOXALINE; 1,2,4 TRIAZO[4,3 A] QUINOXALINE; 2 (3 HYDROXY 4,5,6,7 TETRAHYDROINDAZOL 2 YL) 3 PHENYLQUINOXALINE; 2 (3 OXO 3,3A,4,5,6,7 HEXAHYDROINDAZOL 2 YL) 3 PHENYLQUINOXALINE; 2 (4 PHENYL 1,2,4 TRIAZOLO[4,3 A]QUINOXALIN 1 YL)BENZOIC AID; 2 [(ETHOXYCARBONYLCYCLOPENTAN 2YLIDEN)HYDRAZINO] 3 PHENYLQUINOXALINE; 2 BENZYLIDENHYDRAZINO 3 PHENYLQUINOXALINE; 3 (4 PHENYL 1,2,4 TRIAZOLO[4,3 A]QUINOXALIN 1 YL)PROPANOIC ACID; 4 PHENYL 1,2 HIHYDRO 1,2,4 TRIAZOLO[4,3 A]QUINOXALINE; 4 PHENYL 1,2,4 TRIAZOLO[4,3 A]QUINOXALINE; BENZYLIDENE N' (3 PHENYLQUINOXALINE 2 YL)HYDRAZINE; CEFOTAXIME; N CYCLOPENTYLIDENE (3 PHENYLQUINOXALINE 2 YL)HYDRAZINE; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN CANCER; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; LEUKEMIA; MELANOMA; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; CANDIDA ALBICANS; CEFOTAXIME; CELL LINE, TUMOR; CELL SURVIVAL; DIMETHYLFORMAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; NYSTATIN; QUINOXALINES; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 33750406997     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200600061     Document Type: Article

References (16)

1. N. S. Habib, S. A. El-Hawash, Pharmazie 1997, 52, 594-598.
2. S. A. El-Hawash, N. S. Habib, N. H. Fanaki, Pharmazie 1999, 54, 808-813.
3. N. S. Habib, S. A. El-Hawash, Boll. Chim. Farm. 2005, 144, 1.
4. S. A. El-Hawash, A. E. Abdel Wahab, Arch. Pharm. Chem. Life Sci. 2006, 339, 437-447.
5. D.-I. Shiho, S. J. Tagami, J. Am. Chem. Soc. 1960, 82, 4044-4054.
6. M. M. Badran, K. M. Abouzid, M. H. Hussein, Az. J. Pharm. Sci. 2002, 30, 57-67.
7. G. Westphal, H. Wasicki, U. Zielinski, F. G. Weber, et al., Pharmazie 1977, 32, 687-689.
8. E. A. Badawey, T. Kappe, Arch. Pharm. Pharm. Med. Chem. 1997, 330, 59-62.
9. V. Calotta, D. Catarzi, F. Varano, L. Cecchi, et al., Arch. Pharm. Med. Chem. 1997, 330, 387-391.
10. E. A. Badawey, J. Heterocycl. Chem. 1996, 33, 229-233.
11. M. M. Badran, K. A. Abouzid, M. H. Hussein, Arch Pharm. Res. 2003, 26, 107-113.
12. E. A. Badawey, I. M. El-Ashmawey, Eur. J. Med. Chem. 1998, 33, 349-361.
13. [13) M. R. Grever, S. A. Schepartz, B. A. Chabner, Semin. Oncol. 1992, 19, 622-638.
14. M. R. Boyed, K. D. Paull, Drug Rev. Res. 1995, 34, 91-109.
15. A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, et al., J. Natl. Caner Inst. 1991, 83, 757-766.
16. S. R. Jain, A. Kar, Planta Med. 1971, 20, 118-123.